HRSA responds to AHA outreach regarding Johnson & Johnson’s unilateral imposition of 340B rebate model 

Aug 23, 2024 - 02:34 PM
340B pic

Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products, Stelara and Xarelto. Starting Oct. 15, J&J will require all disproportionate share hospitals participating in the 340B Drug Pricing Program to purchase these drugs at full price and submit data to J&J. Upon verification of the drug’s 340B status, DSHs would receive a rebate for the discounted 340B price.

Last week, the AHA contacted the Health Resources and Services Administration for more information as soon as it was made aware that J&J was considering these actions. HRSA notified the AHA today that it has informed J&J that its rebate model is inconsistent with the 340B statute and that this model has not been approved by the Secretary of the Department of Health and Human Services. HRSA further informed the AHA that it will take appropriate action as warranted.
 

Related News Articles

Headline
Report highlights how 340B arrangements with community and specialty pharmacies improve access to care for underserved patients
The AHA Sept. 9 released a report highlighting how hospitals’ arrangements with community and specialty pharmacies improve access to care for underserved…
Headline
Report: District court denies preliminary injunction, upholding Maryland law protecting 340B pricing for contract pharmacy arrangements
A district court in Baltimore Sept. 5 ruled against drug companies and PhRMA, denying their attempt to obtain a preliminary injunction against 340B pricing for…
Headline
AHA files amicus brief in Missouri to prevent injunction against 340B pricing for contract pharmacy arrangements
The AHA, 340B Health and the American Society of Health-System Pharmacists last week filed an amicus brief in a federal district court in Missouri, defending…
Headline
AHA urges HRSA to block J&J’s illegal imposition of 340B rebate model
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the…
Headline
AHA urges HRSA to take immediate enforcement action to block J&J’s illegal imposition of 340B rebate model
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the…
Headline
AHA comments to MedPAC on 2024-2025 cycle 
The AHA Aug. 13 commented to the Medicare Payment Advisory Commission in anticipation of the commission’s 2024-2025 cycle. The AHA urged MedPAC to carefully…